Skip to content
10-Q

Quarterly Report

Apimeds Pharmaceuticals US, Inc. APUS

0001213900-26-061013

← back to feed
Filed
May 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 26, 2026 15.09M sh
Shares Diluted Q1 2026 · Mar 31, 2026 15.51M sh
Shares Diluted Q1 2026 · Mar 31, 2025 7.9M sh
Capex Q1 2026 · Mar 31, 2026 $9.39K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.07M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$20.31K
Short Term Investments Q1 2026 · Mar 31, 2026 $1.5M
Short Term Investments Q1 2026 · Dec 31, 2025 $2M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $979.53K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $1.64M
Cash And Equivalents restated Q1 2026 · Mar 31, 2025 $250.43K
Stockholders Equity Q1 2026 · Mar 31, 2026 $126.52M
Stockholders Equity Q1 2026 · Dec 31, 2025 $153.35M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$1.76M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$1.36M
Current Liabilities Q1 2026 · Mar 31, 2026 $14.58M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.71M
Total Liabilities Q1 2026 · Mar 31, 2026 $14.7M
Total Liabilities Q1 2026 · Dec 31, 2025 $10.84M
Current Assets Q1 2026 · Mar 31, 2026 $13.15M
Current Assets Q1 2026 · Dec 31, 2025 $13.98M
Total Assets Q1 2026 · Mar 31, 2026 $141.22M
Total Assets Q1 2026 · Dec 31, 2025 $164.18M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.26
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.05
Eps Basic Q1 2026 · Mar 31, 2026 −$2.26
Eps Basic Q1 2026 · Mar 31, 2025 −$0.05
Sga Expense Q1 2026 · Mar 31, 2026 $11.28M
Sga Expense Q1 2026 · Mar 31, 2025 $364.37K
Rd Expense Q1 2026 · Mar 31, 2026 $901.14K
Net Income Q1 2026 · Mar 31, 2026 −$35.06M
Net Income Q1 2026 · Mar 31, 2025 −$402.4K
Operating Income Q1 2026 · Mar 31, 2026 −$12.19M
Operating Income Q1 2026 · Mar 31, 2025 −$364.37K